-transparent.png){kind=logo}
Nifedipine, a dihydropyridine calcium antagonist, improves endothelial function in patients with hypercholesterolaemia by enhancing nitric oxide (NO) activity, and increases endothelial NO bioavailability by antioxidant mechanisms. We administered a long-acting nifedipine formulation (controlled release (CR) nifedipine: 20 mg/day) to hypertensive patients for 6 months. There were no other changes of drug treatment during therapy with CR nifedipine. Clinical and biochemical data obtained before and after CR nifedipine administration were compared. All markers were measured by enzyme-linked immunosorbant assay. The levels of soluble markers (soluble CD40 ligand, soluble P-selectin, and soluble E-selectin), microparticles (MP) (platelet-derived MP, monocyte-derived MP, and endothelial cell-derived MP), and adiponectin differed between the control group and the hypertension group. The levels of these markers were also different in hypertensive patients with and without type 2 diabetes compared with the control group. In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment. In contrast, markers were unchanged in the hypertensive patients without type 2 diabetes. Adiponectin was increased after 6 months of CR nifedipine treatment in hypertensive patients with type 2 diabetes. The effects of CR nifedipine on platelet/monocyte activation and adiponectin levels demonstrated in the present study indicate the potential effectiveness of calcium antagonist therapy for hypertensive patients with type 2 diabetes.
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
January 2006,
Thrombosis research,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
July 2017,
British journal of clinical pharmacology,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
November 2006,
Yao xue xue bao = Acta pharmaceutica Sinica,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
March 1993,
American journal of hypertension,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
January 2006,
Drugs,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
January 2008,
Terapevticheskii arkhiv,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
January 2001,
Journal of atherosclerosis and thrombosis,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
April 2011,
Expert opinion on therapeutic targets,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
November 1987,
European heart journal,
S Nomura, and
N Inami, and
Y Kimura, and
S Omoto, and
A Shouzu, and
M Nishikawa, and
T Iwasaka
April 2013,
Atherosclerosis,
